Therefore, we defined the low-risk group for nodal metastasis as patients who demonstrated the following clinical features: serum CA125 < 30.0 IU/mL, tumor with either or both of positive PR staining > 50% and Ki67 < 40%. This evidence concerns the gene MUC16 and neoplasm.